Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia
Paul J. Hampel(Mayo Clinic), Wei Ding(Mayo Clinic), Sameer A. Parikh(Mayo Clinic), Mithun Vinod Shah(Mayo Clinic in Arizona), Min Shi(Mayo Clinic in Arizona), Susan M. Schwager(Mayo Clinic in Arizona), Timothy G. Call(Mayo Clinic), Saad S. Kenderian(Mayo Clinic in Arizona), Amber B. Koehler(Mayo Clinic in Arizona), Daniel L. Van Dyke(Mayo Clinic), Susan L. Slager(Mayo Clinic), N. Nora Bennani(Mayo Clinic in Arizona), Eli Muchtar(Mayo Clinic), Kari G. Rabe(Mayo Clinic), Curtis A. Hanson(Toyota Motor Corporation (Switzerland)), Yucai Wang(Mayo Clinic), Neil E. Kay(Mayo Clinic), José F. Leis(Mayo Clinic), Aref Al‐Kali(Mayo Clinic)
Cited by 12
Related Papers
Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
|New England Journal of Medicine|2014|1.6k
Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials
|JAMA Oncology|2019|829
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2019|735
Systematic Review and Meta-Analysis of the Efficacy of Appropriate Empiric Antibiotic Therapy for Sepsis
|Antimicrobial Agents and Chemotherapy|2010|727